Page 2 - Toronto Memory Program News Today

The Cambridge biotech is a pioneer in medicines that rely on RNA interference, a scientific innovation that “silences” disease-causing genes.

Lecanemab was shown to slow cognitive decline in early Alzheimer’s disease and reduce the number of amyloid plaques.

Lecanemab was hailed by headlines as a breakthrough treatment for Alzheimer's. Now, with the death of a third patient, there are concerns about this medication.

Steve McNeil recently skated his 35th marathon to raise awareness and funds for Alzheimers societies across Canada, while a new drug recently approved by the U.S. Food and Drug Administration

Three-decade hockey referee and mailman Steve McNeil of Etobicoke hits the ice on Saturday for his 35th skating marathon for Alzheimer’s — and he’s asking Torontonians and Canadians to join

Federal drug regulators on Friday approved lecanemab, sold under the brand name Leqembi, an Alzheimer’s drug that appears to slow the disease.

Federal drug regulators on Friday approved lecanemab, sold under the brand name Leqembi, an Alzheimer’s drug that appears to slow the disease.

The death of a participant in a clinical trial of an antibody treatment for Alzheimers disease, which is now under consideration by the FDA, may be linked to the experimental drug, a new report shows.

- Expert panel to provide proactive, evidence-informed recommendations that are costed and implementable - A panel of 17 leading experts in dementia care

A drug that offers a small benefit to Alzheimer's patients is making a big splash with doctors who treat the disease.The drug, a monoclonal antibody called lecanemab, dominated last week's Cli